庫爾特·凱斯特(Kurt R.自2005年要求以來的工程已經多年了。
由安妮·瑪麗·墨菲(Anne Marie Murphy)撰寫 - FDA本周宣布出版了《臨床調查監督:一種基於風險的監測方法》的指南草案。這是自1988年以來的第一次,該機構發布了有關研究讚助商的特定指導文件。
Ricardo Carvajal撰寫 - 6月,我們報告說,DC巡回上訴法院認為,它缺乏對自然資源國防委員會(“ NRDC”)公民請願書的專屬管轄權,要求尋求FDA針對BPA的行動。NRDC毫無疑問,現在已向地方法院提起申訴。投訴…
By William T. Koustas & John R. Fleder – Google, Inc. (“Google”) and the Department of Justice (“DOJ”) (acting in concert with FDA’s Office of Criminal Investigations) have settled the government’s criminal investigation into Google’s AdWords program, which displayed advertisements on websites for online Canadian pharmacies. …
By Riëtte van Laack – Under the law, a manufacturer of a new dietary ingredient ("NDI") or a dietary supplement containing an NDI must notify FDA of the basis for the manufacturer’s conclusion that its product “will reasonably be expected to be safe.” FDA’s regulation, 21 …
由Ricardo Carvajal撰寫 - Del Monte Fresh Produce N.A.,Inc。(“ Del Monte Fresh”)被起訴,以無效從S.A. Productos Agricolas de Oriente(“ Pao”)對Chataloupe的FDA進口警報無效,這是Guatemalan生產商之一,是Del Monte的一員Fresh’s principal suppliers. FDA imposed the import alert …
在一年中的那個時候,我們在FDA Law Blog轉向忠實的讀者說:“我們的博客家,不要問您的博客可以為您做什麼 - 問您可以為博客做什麼。”是的,美國律師協會…
作者:Kurt R. Karst - 最近,我們報道了有關Medicines Company(“ MDCO”)Angiomax(Bivalirudin)注射的橙皮書中列出的“其他戰鬥”。據報道,隨著奧巴馬總統議程的高度改革,隨著9月6日的迅速回歸……
By Cassandra A. Soltis – In response to the Food and Drug Administration’s (“FDA’s”) proposed rule on nutrition labeling of standard menu items in restaurants and similar retail food establishments, members of the U.S. Senate and House of Representatives have requested that FDA exclude grocery stores …
作者:Kurt R. Karst - 本周早些時候,由五家煙草公司組成的集團(R.J. Reynolds煙草公司,Lorillard煙草公司,Commonwealth Brands,Inc。,Liggett Group LLC和Santa Fe Fe Fe Natural Tobacco Company,Inc。)計算美國地方法院對FDA的投訴……
詹妮弗·D·紐伯格(Jennifer D. Newberger) - 2011年8月15日,FDA發布了兩種指導草案:“在醫療設備預審查中做出福利風險確定時要考慮的因素”和“針對醫療設備的關鍵臨床研究的設計注意事項”。依次在下麵討論每個。製作…時要考慮的因素
By Kurt R. Karst – The court battle over the “new drug” status of Cody Laboratories, Inc.’s and Lannett Co., Inc.’s (collectively “Cody/Lannett’s”) Morphine Sulfate Oral Solution 20mg/mL drug product has taken a new turn. FDA’s Motion to Dismiss the case on mootness grounds has been …
作者:RiëtteVanLaack - FDA正在重新開放有關其於2010年12月8日發布的擬議規則的評論期,以修改植物固醇/黴菌的法規和冠狀動脈疾病的風險。(請參閱我們先前關於擬議規則的文章。)FDA提議的一位…
By Kurt R. Karst – With all of the hullabaloo that has been going on in court and on Capitol Hill in the continuing battle over a Patent Term Extension (“PTE”) for U.S. Patent No. 5,196,404 (“the ‘404 Patent”) covering The Medicines Company’s (“MDCO’s”) ANGIOMAX (bivalirudin) …